Log In
Print
BCIQ
Print
Print this Print this
 

Subcutaneous Actemra, tocilizumab

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSubcutaneous formulation of a humanized mAb against IL-6 receptor
Molecular Target Interleukin-6 (IL-6) receptor (CD126)
Mechanism of ActionAntibody
Latest Stage of DevelopmentRegistration
IndicationRheumatoid arthritis (RA)
Partner

Chugai Pharmaceutical Co. Ltd.; Genentech Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today